RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630. Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’...
作者: 王者Pd-1默沙东临床失利,是正常事情。 MRK is discontinuing Phase 3 KEYNOTE-867 trial and Phase 3 KEYNOTE-630 trial#Seeking##biotech#
KEYNOTE-867 was a double-blind study that enrolled patients with unresected stage I or II NSCLC who were medically inoperable, including those who could not undergo thoracic surgery due to illness or an anatomically unresectable tumor, or who decided...
Key studies in earlier stages of NSCLC include KEYNOTE-671, KEYNOTE-091, KEYNOTE-867, KEYLYNK-012 and KEYVIBE-006. About KEYNOTE-671 KEYNOTE-671 is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, NCT03425643...
基于PACIFIC研究成果, 同步放化疗后未进展的Ⅲ期不可切除非小细胞肺癌(non-small cell lung cancer, NSCLC)患者接受度伐利尤单抗巩固治疗已成为标准治疗模式。然而22%~30%的Ⅲ期不可切除NSCLC患者因为不可耐受的治疗相关毒性未能完成同步...
No answers on this topic One Time Purchase $139.99 Offerings Pricing Offerings Apple KeynoteMicrosoft Powerpoint Free Trial NoNo Free/Freemium Version NoNo Premium Consulting/Integration Services NoNo Entry-level Setup FeeNo setup feeNo setup fee ...
10.Faivre-Finn C, Vicente D, Kurata T, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16(5):860-867. 11.Horinouchi H, Atagi S, Oizumi S, et al. Real-world outcomes of chemoradiotherapy for...
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98 J Clin Oncol, 31 (2013), pp. 860-867 View in Sc...
10.Faivre-Finn C, Vicente D, Kurata T, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16(5):860-867. 11.Horinouchi H, Atagi S, Oizumi S, et al. Real-world outcomes of chemoradiotherapy for...
10.Faivre-Finn C, Vicente D, Kurata T, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16(5):860-867. 11.Horinouchi H, Atagi S, Oizumi S, et al. Real-world outcomes of chemoradiotherapy for...